| Identification | Back Directory | [Name]
AZD-1390 | [CAS]
2089288-03-7 | [Synonyms]
CS-2816
AZD-1390
AZD-1390;AZD 1390
7-Fluoro-1,3-dihydro-3-methyl-1-(1-methylethyl)-8-[6-[3-(1-piperidinyl)propoxy]-3-pyridinyl]-2H-imidazo[4,5-c]quinolin-2-one
2H-Imidazo[4,5-c]quinolin-2-one, 7-fluoro-1,3-dihydro-3-methyl-1-(1-methylethyl)-8-[6-[3-(1-piperidinyl)propoxy]-3-pyridinyl]- | [Molecular Formula]
C27H32FN5O2 | [MDL Number]
MFCD31619275 | [MOL File]
2089288-03-7.mol | [Molecular Weight]
477.57 |
| Chemical Properties | Back Directory | [Boiling point ]
617.4±55.0 °C(Predicted) | [density ]
1.224±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO:10.0(Max Conc. mg/mL);20.93(Max Conc. mM)
Ethanol:80.0(Max Conc. mg/mL);168.51(Max Conc. mM) | [form ]
A solid | [pka]
9.22±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
VQSZIPCGAGVRRP-UHFFFAOYSA-N | [SMILES]
N1C2C(=CC(C3=CC=C(OCCCN4CCCCC4)N=C3)=C(F)C=2)C2N(C(C)C)C(=O)N(C)C=2C=1 |
| Hazard Information | Back Directory | [Uses]
AZD 1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor. | [in vivo]
Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390[2]. | [IC 50]
ATM | [storage]
Store at -20°C |
|
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|